Overexpression of is Associated with Cisplatin Resistance and May Depend on MA Modification in Patients with Cervical Cancer

Overview

Journal Oncol Lett

Specialty Oncology

Date 2024 Dec 9

PMID 39650230

Authors

Ruixue Wang

Jiaxing Deng

Meng Zhang

Zhihui Wang

Shangjie Wu

Shilong Liu

Lishuang Qi

Affiliations

Soon will be listed here.

Abstract

Cervical cancer (CC) is the fourth leading cause of cancer-associated mortalities among women worldwide. The chemotherapeutical platinum-based agent cisplatin (DDP) is the standard therapy for locally advanced or recurrent CC; however, platinum resistance limits its clinical benefit. Therefore, the present study aimed to identify key genes associated with DDP resistance in patients with CC and investigate the underlying molecular mechanisms. Firstly, using the CRISPR-Cas9 dataset of CC cells derived from DepMap portal, 699 genes associated with CC cell survival were identified. Subsequently, using the gene expression profiles of normal and CC samples with a response status to DDP, derived from The Cancer Genome Atlas (TCGA), hypoxia upregulated 1 () was further identified as significantly upregulated in CC samples and patients that did not respond to DDP (non-responders) when compared with healthy controls and patients that did respond to DDP (responders), respectively, using unpaired student's t-tests. Additionally, the log-rank test revealed that the high expression of was significantly associated with the poor survival of patients receiving DDP. The association between the high expression levels and the poor survival of patients receiving DDP was validated in the remaining TCGA dataset of patients with CC. expression levels were positively associated with the half-maximal inhibitory concentration value of DDP in CC cells using data derived from the Genomics of Drug Sensitivity in Cancer database. , western blotting experiments revealed high HYOU1 protein expression levels in DDP-resistant HeLa cells compared with their parental HeLa cells. Furthermore, the knockdown of resulted in an increased sensitivity of HeLa cells to DDP. Finally, using the sequence-based RNA adenosine methylation site predictor program, it was found that N-methyladenosine (mA) was highly enriched in HYOU1. The expression levels of the mA reader, , was positively correlated with the expression levels of and was upregulated in the non-response group compared with the response group in a dataset from TCGA database. Additionally, had the highest probability of binding to the mA motifs of compared with other genes. In GSE56363 obtained from the Gene Expression Omnibus, the non-responders had significantly increased expression levels of compared with the responders. In conclusion, high expression levels of , which may be regulated by due to mA modifications, was associated with DDP resistance in patients with CC and could potentially be used as an indicator of DDP treatment resistance.

References

Lorusso D, Petrelli F, Coinu A, Raspagliesi F, Barni S . A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer. Gynecol Oncol. 2014; 133(1):117-23. DOI: 10.1016/j.ygyno.2014.01.042. View

Liao Y, Wang J, Jaehnig E, Shi Z, Zhang B . WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs. Nucleic Acids Res. 2019; 47(W1):W199-W205. PMC: 6602449. DOI: 10.1093/nar/gkz401. View

Jiang X, Liu B, Nie Z, Duan L, Xiong Q, Jin Z . The role of m6A modification in the biological functions and diseases. Signal Transduct Target Ther. 2021; 6(1):74. PMC: 7897327. DOI: 10.1038/s41392-020-00450-x. View

Fu Y, Dominissini D, Rechavi G, He C . Gene expression regulation mediated through reversible m⁶A RNA methylation. Nat Rev Genet. 2014; 15(5):293-306. DOI: 10.1038/nrg3724. View

Desrosiers R, Friderici K, Rottman F . Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells. Proc Natl Acad Sci U S A. 1974; 71(10):3971-5. PMC: 434308. DOI: 10.1073/pnas.71.10.3971. View

Zhou Y, Liao Q, Li X, Wang H, Wei F, Chen J . HYOU1, Regulated by LPLUNC1, Is Up-Regulated in Nasopharyngeal Carcinoma and Associated with Poor Prognosis. J Cancer. 2016; 7(4):367-76. PMC: 4749358. DOI: 10.7150/jca.13695. View

Yang W, Soares J, Greninger P, Edelman E, Lightfoot H, Forbes S . Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2012; 41(Database issue):D955-61. PMC: 3531057. DOI: 10.1093/nar/gks1111. View

Meyers R, Bryan J, McFarland J, Weir B, Sizemore A, Xu H . Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat Genet. 2017; 49(12):1779-1784. PMC: 5709193. DOI: 10.1038/ng.3984. View

Liu J, Harada B, He C . Regulation of Gene Expression by N-methyladenosine in Cancer. Trends Cell Biol. 2019; 29(6):487-499. PMC: 6527461. DOI: 10.1016/j.tcb.2019.02.008. View

10.

Bai Z, Wang Y, Zhe H, He J, Hai P . ERCC1 mRNA levels can predict the response to cisplatin-based concurrent chemoradiotherapy of locally advanced cervical squamous cell carcinoma. Radiat Oncol. 2012; 7:221. PMC: 3536645. DOI: 10.1186/1748-717X-7-221. View

11.

Xuan J, Sun W, Lin P, Zhou K, Liu S, Zheng L . RMBase v2.0: deciphering the map of RNA modifications from epitranscriptome sequencing data. Nucleic Acids Res. 2017; 46(D1):D327-D334. PMC: 5753293. DOI: 10.1093/nar/gkx934. View

12.

Knuckles P, Lence T, Haussmann I, Jacob D, Kreim N, Carl S . Zc3h13/Flacc is required for adenosine methylation by bridging the mRNA-binding factor Rbm15/Spenito to the mA machinery component Wtap/Fl(2)d. Genes Dev. 2018; 32(5-6):415-429. PMC: 5900714. DOI: 10.1101/gad.309146.117. View

13.

Zhu H, Luo H, Zhang W, Shen Z, Hu X, Zhu X . Molecular mechanisms of cisplatin resistance in cervical cancer. Drug Des Devel Ther. 2016; 10:1885-95. PMC: 4907638. DOI: 10.2147/DDDT.S106412. View

14.

Li X, Zhang N, Ye H, Song P, Chang W, Chen L . HYOU1 promotes cell growth and metastasis via activating PI3K/AKT signaling in epithelial ovarian cancer and predicts poor prognosis. Eur Rev Med Pharmacol Sci. 2019; 23(10):4126-4135. DOI: 10.26355/eurrev_201901_17914. View

15.

Rao S, Oyang L, Liang J, Yi P, Han Y, Luo X . Biological Function of HYOU1 in Tumors and Other Diseases. Onco Targets Ther. 2021; 14:1727-1735. PMC: 7943547. DOI: 10.2147/OTT.S297332. View

16.

Nombela P, Miguel-Lopez B, Blanco S . The role of mA, mC and Ψ RNA modifications in cancer: Novel therapeutic opportunities. Mol Cancer. 2021; 20(1):18. PMC: 7812662. DOI: 10.1186/s12943-020-01263-w. View

17.

Visioli F, Wang Y, Alam G, Ning Y, Rados P, Nor J . Glucose-regulated protein 78 (Grp78) confers chemoresistance to tumor endothelial cells under acidic stress. PLoS One. 2014; 9(6):e101053. PMC: 4071032. DOI: 10.1371/journal.pone.0101053. View

18.

Yi Y, Zhao Y, Huang Y, Wang D . A Brief Review of RNA-Protein Interaction Database Resources. Noncoding RNA. 2018; 3(1). PMC: 5832006. DOI: 10.3390/ncrna3010006. View

19.

Huang H, Weng H, Chen J . mA Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer. Cancer Cell. 2020; 37(3):270-288. PMC: 7141420. DOI: 10.1016/j.ccell.2020.02.004. View

20.

Liu J, Wang Y . Long non-coding RNA KCNQ1OT1 facilitates the progression of cervical cancer and tumor growth through modulating miR-296-5p/HYOU1 axis. Bioengineered. 2021; 12(1):8753-8767. PMC: 8806506. DOI: 10.1080/21655979.2021.1982230. View